PRTA Prothena Corporation plc

-0.02  -0%
Previous Close 13.05
Open 13.01
Price To Book 1.46
Market Cap 519073973
Shares 39,836,836
Volume 619,241
Short Ratio 10.57
Av. Daily Volume 430,418

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2020.
Parkinson's disease
Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.
Psoriatic Arthritis
Phase 3 trial discontinued due to futility - April 23, 2018.
AL Amyloidosis
Phase 2b trial did not meet primary endpoint - April 23, 2018.
Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction
Phase 1 preliminary data due 2019.
ATTR amyloidosis

Latest News

  1. Factors of Influence in 2018, Key Indicators and Opportunity within 1-800 FLOWERS.COM, Bojangles', Prothena Corporation plc, Lydall, Daktronics, and ServiceSource International — New Research Emphasizes Economic Growth
  2. Celgene's Otezla Meets Goal in Scalp Plaque Psoriasis Study
  3. Are Options Traders Betting on a Big Move in Prothena (PRTA) Stock?
  4. The Law Offices of Howard G. Smith Reminds Investors of Extended Lead Plaintiff Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
  5. September 17th Deadline Alert: Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Prothena Corporation plc (PRTA)
  6. Why Is Prothena (PRTA) Up 8.2% Since Last Earnings Report?
  7. EQUITY NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Prothena Corporation plc – PRTA
  8. Glancy Prongay & Murray LLP Announces Extended Lead Plaintiff Deadline in Securities Class Action on Behalf of Prothena Corporation plc Investors (PRTA)
  9. Is Celgene Set to See Improved Results in the Second Half?
  10. Investor Expectations to Drive Momentum within Rapid7, 1-800 FLOWERS.COM, SMART Global, Prothena Corporation plc, Amphastar Pharmaceuticals, and Silvercorp Metals — Discovering Underlying Factors of Influence
  11. Notice of Voluntary Dismissal of Class Action Concerning Prothena Corporation
  12. Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
  13. Prothena (PRTA) Reports Q2 Loss, Tops Revenue Estimates
  14. Prothena: 2Q Earnings Snapshot
  15. Prothena Reports Second Quarter 2018 Financial Results and Provides R&D Update
  16. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Filed a Complaint to Recover Losses Suffered by Prothena Corporation Investors and Set a Lead Plaintiff Deadline of October 5, 2018
  17. Prothena (PRTA) Q2 Earnings: Is a Disappointment in Store?
  18. Prothena to Report Second Quarter 2018 Financial Results on August 7

SEC Filings

  1. 8-K - Current report 181094306
  2. CT ORDER - Confidential treatment order 181031734
  3. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 181026376
  4. S-8 - Securities to be offered to employees in employee benefit plans 181005188
  5. 10-Q - Quarterly report [Sections 13 or 15(d)] 18998488
  6. 8-K - Current report 18998305
  7. 8-K - Current report 18969507
  8. 8-K - Current report 18917207
  9. 8-K - Current report 18861674
  10. 8-K - Current report 18844512